Phio Pharmaceuticals (PHIO) Shares Outstanding (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Shares Outstanding (Entity) came in at $11.6 million in Q1 2026, up 143.13% YoY from $4.8 million in Q1 2025, and up 94.14% on a QoQ basis from $6.0 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Shares Outstanding (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Shares Outstanding (Entity) data on file, last reported at $11.6 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 143.13% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 143.13% YoY) and the FY2025 annual result came in at $6.0 million, up 659.91% from the prior year.
- Shares Outstanding (Entity) climbed to $11.6 million in Q1 2026, from $6.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $192.1 million in Q2 2023 to a low of $126463.0 in Q1 2022.
- A 5-year average of $13.5 million and a median of $510188.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 151764.6% — and 2024, when it tumbled 99.73%.
- Tracing PHIO's Shares Outstanding (Entity) over 5 years: stood at $126557.0 in 2022, then soared by 82.93% to $231505.0 in 2023, then surged by 240.15% to $787466.0 in 2024, then jumped by 659.91% to $6.0 million in 2025, then soared by 94.14% to $11.6 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $11.6 million (Q1 2026), $6.0 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 11.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.62 Mn |
| Mar 31, 2026 | 11.62 Mn |
| Dec 31, 2025 | 5.98 Mn |
| Sep 30, 2025 | 5.47 Mn |
| Jun 30, 2025 | 4.79 Mn |
| Mar 31, 2025 | 4.31 Mn |
| Dec 31, 2024 | 787,466.00 |
| Sep 30, 2024 | 990,033.00 |
| Jun 30, 2024 | 510,188.00 |
| Mar 31, 2024 | 508,892.00 |
| Dec 31, 2023 | 231,505.00 |
| Sep 30, 2023 | 271,127.00 |
| Jun 30, 2023 | 192.05 Mn |
| Mar 31, 2023 | 126,911.00 |
| Dec 31, 2022 | 126,284.00 |
| Sep 30, 2022 | 126,502.00 |
| Jun 30, 2022 | 126,463.00 |
| Mar 31, 2022 | 125,588.00 |
| Dec 31, 2021 | 118,798.00 |
| Sep 30, 2021 | 125,314.00 |